Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library

School of Medicine

1-1-2018

Adherence To Prospective Registration Policy And Implications
For Clinical Trial Endpoint Integrity
Anand Gopal

Follow this and additional works at: https://elischolar.library.yale.edu/ymtdl
Part of the Medicine and Health Sciences Commons

Recommended Citation
Gopal, Anand, "Adherence To Prospective Registration Policy And Implications For Clinical Trial Endpoint
Integrity" (2018). Yale Medicine Thesis Digital Library. 3400.
https://elischolar.library.yale.edu/ymtdl/3400

This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A
Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital
Library by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more
information, please contact elischolar@yale.edu.

Adherence to Prospective Registration Policy and Implications for Clinical Trial
Endpoint Integrity

A Thesis Submitted to the
Yale University School of Medicine
in Partial Fulfillment of the Requirements for the
Degree of Doctor of Medicine

by
Anand D. Gopal
2018

Abstract
ADHERENCE TO PROSPECTIVE REGISTRATION POLICY AND IMPLICATIONS
FOR CLINICAL TRIAL ENDPOINT INTEGRITY
Anand D. Gopal, Joshua D. Wallach, Jenerius A. Aminawung, Gregg Gonsalves, Rafael Dal-Ré, Jennifer
E. Miller, Joseph S. Ross.
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT

Abstract: Since implementation of the International Committee of Medical Journal Editors’ (ICMJE)
prospective registration policy in 2005, trial registration has increased significantly. Registering
clinical trials is critical in promoting transparency and integrity in medical research, however trials
must be registered in an appropriate manner to deter unaccounted protocol modifications or
selection of alternate endpoints that may enhance favorability of reported results. This thesis
provides relevant background on clinical trial registration and appropriate reporting in addition to
evaluating adherence with the ICMJE’s prospective trial registration policy and the implications of
inappropriate adherence for the integrity of reported results. In a cross-sectional, retrospective
analysis of recent trials published in the highest-impact journals associated with US professional
medical societies, we identified the frequency of registrations occurring late in addition to those late
enough to potentially permit protocol modifications based on premature examination of collected
data. We further examined whether trials that are unregistered or registered late enough to permit
interim analyses were more likely to report favorable results. We used descriptive statistics to
characterize the proportions of trials that were: registered; registered retrospectively; registered
retrospectively potentially after initial ascertainment of primary endpoints; and reporting favorable
results, overall and stratified by journal and trial characteristics. Among 486 trials published
between January 1, 2010 and December 31, 2015, 47 (10%) were unregistered. Among 439
registered trials, 340 (77%) were registered prospectively and 99 (23%) retrospectively. Sixty-seven
(68%) of these 99 retrospectively registered trials, or 15% of all 439 registered trials, were
registered late enough to have potentially permitted premature examination of primary endpoint

data ascertained among participants enrolled at inception. Unregistered trials were more likely to
report favorable results than registered trials (89% vs. 64%; p=0.004), irrespective of registration
timing. Adherence to the ICMJE’s prospective registration policy remains sub-standard, even in the
highest impact journals associated with US professional medical societies. These journals frequently
published unregistered trials and trials registered late enough to have potentially experienced
unaccounted protocol modifications after observation of primary endpoints.
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INTRODUCTION
Universal registration of clinical trials is critical for promoting transparency
and integrity in medical research, helping to ensure a complete and unbiased record
of all clinical trials.[1-3] Clinical trial registration is defined as the “systematic public
disclosure of key descriptive information about a clinical trial.”[4] Registration
alone, however, is insufficient, as trials must be registered in a timely fashion to
deter selective reporting, which may include addition or removal of endpoint
measures, preferential publication of statistically significant findings, and
modification of which endpoint measures were pre-specified as primary.[5]
Accordingly, registering trials prospectively, or before enrollment of participants,
helps foster integrity and confidence in the clinical research enterprise by limiting
the opportunity for interim analyses to distort the validity of reported results.
Rationale for Clinical Trial Transparency
Clinical trials represent the primary mechanism through which novel
laboratory discoveries are initially applied to human subjects and through which
therapies and interventions garner evidence in favor of or against standard use. The
knowledge derived from clinical trials forms the foundation for the evidence used to
drive medical decision-making, as trial data are frequently fed into systematic
reviews and meta-analyses. The aggregate findings from these larger analyses
generate a more robust, unbiased evidence base than can be discerned from
individual studies alone, though depend critically on the completeness and accuracy
of the individual studies from which they draw. Because of their pivotal
contributions to broader analyses, clinical trials must be disclosed and their results
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made readily accessible. Otherwise, clinical decisions may be biased by the selective
availability of clinical trial information, placing patients at risk by subjecting them to
care based on partial evidence. In the absence of systematic public disclosure, data
from clinical trials are limited to those disseminated through peer-reviewed
publications or presented at scientific meetings, a limitation known as publication
bias.[1, 6, 7] As studies reporting significant findings are more frequently published
than those reporting null findings, publication bias risks a body of evidence that
overestimates benefits and exposes patients to suboptimal interventions supported
by skewed or inconsistent data.[2] Registering clinical trials precludes publication
bias by helping to facilitate the incorporation of unpublished knowledge into the
medical evidence base.
Because of their significance in driving medical decision-making, clinical
trials must be consistently held to the highest standards of integrity and scientific
rigor.[8] Besides fulfilling an ethical mandate to trial volunteers, who knowingly
assume risk to advance science, registering clinical trials provides a mechanism to
safeguard the integrity of studies and deter scientific fraud and misconduct.[9] The
systematic disclosure of summary information about a trial enables scientists and
the public to critically assess the integrity of a trial’s design as it was intended and
provides accountability in the reporting of analyses and endpoints. More practically,
registration offers a means for the scientific community and the public to learn
about ongoing and completed trials as well as to assess the allocation of and prevent
the unnecessary duplication of research efforts. These benefits can be realized only
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if trials are not only uniformly registered, but also registered in a timely fashion and
with sufficient detail.[10]
Evolution of Trial Registration and the ICMJE Policy
Recognizing the potential for greater transparency to mitigate the influence
of publication and selective reporting biases and in response to high-profile
controversies involving lack of transparency and suppression of evidence within the
pharmaceutical industry,[9] various governing bodies and organizations have in the
last couple decades developed legal and editorial measures to promote the
prospective registration of clinical trials. Among the first to do so was the
International Committee of Medical Journal Editors (ICMJE), an editorial body
comprising leading biomedical journals whose guidelines and policies set the
standards for ethics and conduct in the publication of biomedical research. In
September 2004, the ICMJE adopted a policy to encourage timely clinical trial
registration, mandating that all trials beginning July 2005 register prospectively, at
or before the time of first patient enrollment, as a condition for publication in its
member journals.[11] Since implementation of the ICMJE policy, efforts to augment
clinical trial transparency have born fruit through a series of policies and
regulations requiring the registration and reporting of clinical trial information. In
2006, the World Health Organization (WHO) released a statement endorsing the
registration of all clinical trials in addition to declaring a minimum set of requisite
information that should be specified upon trial registration. While the Food and
Drug Administration Modernization of Act (FDAMA) of 1997 established the first
federal legal mandate for trial registration in the United States, requiring the
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registration of a subset of trials studying the interventions for patients with serious
or life threatening diseases, the Food and Drug Administration Amendments Act
(FDAAA) of 2007 expanded federal registration requirements to include all nonPhase I trials of FDA-regulated interventions, namely drugs, devices, and biologics.
The law also defined monetary penalties for failure to comply in addition to
outlining requirements for trial results reporting. More recently, the National
Institutes of Health (NIH) has issued a policy requiring registration and results
reporting for all NIH-funded clinical trials with the penalty of suspension of NIHfunding for investigators found to be in violation of these requirements.[4]
Nevertheless, among existing efforts to promote clinical trial registration, the ICMJE
policy remains the most inclusive in scope, applying to all clinical trials regardless of
study type, intervention, or funding source. In this regard, the ICMJE policy
represents the broadest-reaching device in the push toward universal trial
registration, though, without legal or fiduciary jurisdiction, it relies critically on
journals refusing to publish inadequately registered trials as its primary mechanism
of enforcement.
Current Trial Registration Landscape
Since implementation of the ICMJE policy, trial registration at
ClinicalTrials.gov, the largest international clinical trial registry, and other trial
registries has increased substantially.[12] In the five-month period surrounding
implementation of ICMJE’s trial registration policy alone, the number of
registrations on ClinicalTrials.gov grew by 73 percent.[12] However, despite nearly

5
a decade since the policy went into effect, a small but significant number of trials
remain unregistered, including those that are published.[13-19]
Moreover, despite increasing rates of registration, timely registration of trials
is still lacking.[13, 14, 17-22] A recent analysis published in 2017 demonstrated that
nearly one-third of interventional trials registered on ClinicalTrials.gov between
2012 and 2014 were registered more than three months after their start dates and
nearly a fifth were registered more than a year after,[23] suggesting that large
numbers of clinical studies are registered late and hence may be vulnerable to
unaccounted protocol modifications. While ICMJE policy mandates prospective
registration as a prerequisite for publication, retrospectively registered trials
continue to enter the published literature. Previous research suggests that even in
the highest-impact general medical journals, 28% of published trials were
registered retrospectively.[21] In some cases, registration occurred late enough to
raise concerns about whether the specified primary outcome measure had been
modified after trial inception,[21] as retrospective registration may provide
opportunity for unaccounted protocol modifications or selection of alternate
endpoints to enhance the favorability of reported results. Although more than 2,900
journals support general ICMJE manuscript publication guidelines,[24] a 2014
survey found that journal editors do not consistently adhere to ICMJE’s prospective
trial registration policy.[25, 26]
While previous studies of journal adherence to the ICMJE prospective trial
registration policy have thus far either focused on the highest-impact general
medical journals or sampled within field-specific journals, [13, 14, 17-21] little is
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known about registration of trials published among high-impact specialty society
journals. Specialty society journals, administered by professional organizations (e.g.
the American Society of Clinical Oncology), tend to represent the views of their
constituent specialists. They publish trials that are of great interest to their
respective communities, which influence mainstream clinical practice.[27] Although
specialty journals typically have lower impact factors than the highest-impact
general medical journals, they are often a preferred source of clinical information
and guidelines for specialists.[28]
Statement of Purpose
The purpose of this study was to assess adherence to the ICMJE’s prospective
clinical trial registration policy among a large sample of clinical trials recently
published in the ten highest-impact specialty journals affiliated with US professional
medical specialty societies. Specifically, this study evaluated rates of prospective
trial registration; identified instances of registration occurring late enough to
potentially permit premature examination of collected data; and determined
characteristics associated with timely registration. Further, this study compared
registered and published primary endpoints among prospectively and
retrospectively registered trials and identified predictors of endpoint concordance.
Finally, this study examined whether trials that were unregistered or
registered late enough to potentially permit interim analyses were more likely to
report favorable study results. Because failing to register trials or registering trials
retrospectively creates opportunity for investigators to selectively report primary
endpoints with the intent of increasing the trial’s attractiveness for publication, this
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study hypothesized that, among published trials, unregistered trials and those
registered late enough to potentially permit premature primary endpoint
observation will report favorable primary endpoints at a higher rate than trials
registered prospectively in accordance with ICMJE policy.

METHODS
Journal Selection
We identified US specialty society medical journals using a list of US-based
medical professional organizations associated with any of the specialties registered
with the American Board of Medical Specialties. [29] We searched for additional
journals using SCImago Journal & Country Rank listings, adding to our list any
journals associated with a US-based medical specialty organization [30]. We
selected the ten journals with the highest impact factors after excluding general
practice journals and journals that do not publish clinical trials.[31] For each journal
in our sample, we verified endorsement of trial registration as indicated by a
statement on the journal’s website or listing of the journal on the ICMJE’s catalogue
of journals that follow its recommendations as a condition for inclusion.[24]
Clinical Trial Sample Selection
We reviewed original research articles, including brief reports and
communications but not research letters or correspondences, to identify the 50
most recent primary publications of clinical trials in each journal, beginning with
articles published in print journal issues in December 2015 and continuing in
reverse chronology as far back as January 2010. We used the table of contents of
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each print journal issue to identify articles for possible inclusion. One author (A.D.G)
reviewed articles for eligibility in consultation with a senior author (J.S.R.). Clinical
trials were systematically identified by screening the article’s abstract and, if
necessary, the methods section, for statements meeting the WHO’s definition of a
clinical trial, also used by ICMJE, namely any study that “prospectively assigns
people or a group of people to an intervention, with or without concurrent
comparison or control groups, to study the cause-and-effect relationship between a
health-related intervention and a health outcome.”[32]
We limited our sample to publications reporting a trial’s primary analysis,
which is most pertinent to the information contained within its registration, and
excluded trials reporting secondary analyses of previously published results,
secondary outcomes only, or interim analyses of primary endpoints. We further
excluded publications describing Phase I trials, as these studies typically do not
assess effectiveness and have minimal impact, if any, on clinical practice. We
additionally excluded trials beginning prior to July 2005, since trials preceding the
ICMJE policy were unlikely to be prospectively registered.
Data Collection
From trial publications, we extracted information on journal, intervention,
allocation, manuscript submission date, enrollment start date, primary outcome(s)
with associated results, and registration number(s) corresponding to the trial(s)
reported. To account for the possibility of duplicate registrations, we searched the
WHO International Clinical Trials Registry Platform (ICTRP), which aggregates
registrations across registries endorsed by WHO, and in turn endorsed by ICMJE,
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using the reported registration numbers and additionally reviewed registrations for
alternate identifiers to determine the earliest registration for each trial. For
publications not reporting registration information, we searched the WHO ICTRP
platform using search terms pertaining to intervention, first author, senior author,
and sponsor to identify unpublished registrations, cross-referencing potential
matches against sample size and enrollment criteria. We contacted corresponding
authors of unmatched trials for registration information before concluding that the
published trial was unregistered.
Using the earliest registration for each trial, we collected registration date,
primary outcome submission date, primary completion date, start date, primary
outcome(s) at initial registration, enrollment, phase, location, and funding source.
We supplemented information on the latter four elements from trial publications
when missing from the registry. Among trials we determined to have been first
registered on ClinicalTrials.gov, we additionally collected date of original primary
outcome submission, which the registry uniquely lists separately from the trial
registration date. We categorized intervention, funding source, location, enrollment,
and allocation as outlined in Table 1 for use in pre-specified stratified analyses. We
considered interventions involving drugs, devices, or biological as regulated by the
Food and Drug Administration (FDA).
Data abstractions were performed in tandem by A.D.G and J.A.A. Consistency
and accuracy were verified through a 10% random sample validation of each
investigator’s collections. A third author (J.D.W) repeated all searches for trials that
were determined to be unregistered, supplementing with additional searches of the

10
National Institutes of Health (NIH) funding database using grant funding identifiers
when listed in publications.[33] All disagreements were resolved by consensus with
input from the senior investigator (J.S.R).
Main Outcome Measures
We first determined whether each trial was registered by ensuring that a
corresponding registration record could be located. For registered trials, we next
ascertained timeliness of registration by determining whether the trial was
registered within 30 days of its enrollment start date. Although ICMJE policy
mandates registration at or before the time of first patient enrollment, we allowed a
30-day grace period between registration and enrollment initiation in order to
account for potential flexibility on the part of journal editors with regard to
registration timeliness. Month-based representations of dates were recorded as the
last day of the corresponding month (i.e. September 2012 was transcribed as
September 30, 2012) to conservatively classify registrations as “retrospective”. We
elected to use enrollment start dates reported in registries as opposed to those
reported in publications in our determinations of registration timeliness, as we
believed that enrollment start date may not be consistently reported in publications,
while, in registries, it is a mandatory registration element and, hence, less easily
excluded or otherwise misrepresented.
Among trials registered retrospectively, we established whether registration
might have occurred after ascertainment of the primary outcome, and hence
potentially permitted unaccounted protocol modifications after interim analyses, by
comparing the trial’s registration date against the date on which the primary
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outcome would have been collected for the trial’s first enrolled participant(s). For
example, a trial with a primary endpoint assessing serum creatinine levels at 6
weeks that registered in November 2012 but that began enrolling patients in
February 2012 would have been retrospectively registered after observation of the
primary outcome among participants enrolled at the trial’s initiation. In instances
where multiple time frames were designated as primary, we based our calculations
on the shortest primary endpoint time frame specified in the registry. If no time
frame was listed in association with the registered primary outcome, we used the
time frame described in the trial’s publication. We noted cases where the nature of
the primary outcome (e.g. median survival) did not permit this determination.
We next compared primary outcomes at initial registration against those
specified in publications, excluding any primary endpoints pertaining specifically to
safety or tolerability. We classified registered-published primary outcome pairs as
discordant if they differed in any of the following: number of primary outcomes,
definition(s) of primary outcomes, or specified time frame(s) for outcome(s)
ascertainment. If no discrepancies were noted in these three domains, pairs were
classified as concordant. We noted cases where registered endpoints were too
poorly specified (e.g. vague study of “efficacy of intervention”) to permit
comparison. Trials without a designated primary outcome specified in the
publication were excluded from endpoint comparison analyses.
Finally, we categorized each trial on the basis of its primary outcome results
whenever formal hypothesis testing had been conducted or inferences could be
made regarding the statistical significance of reported results (i.e. inferential
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studies). We determined whether the trial’s findings indicated, based on the
reported primary endpoint(s), that a study intervention was statistically
significantly better (i.e. positive), statistically significantly worse (i.e. negative), or
not statistically significantly different (i.e. not significant) than a designated
comparison (placebo group, active group, or predefined threshold) and classified
the overall trial accordingly. For trials that assessed a non-inferiority hypothesis, we
considered establishment of non-inferiority to represent a “positive” result and
failure to establish non-inferiority a “not significant” result. In instances where more
than one primary endpoint was reported, we categorized trials with at least one
significant primary endpoint as “positive” or “negative” on the basis of the
statistically significant endpoint; trials with mixed results (some positive and some
negative primary endpoints) were classified by prioritizing the results of clinical
outcomes over surrogate markers. Trials with mixed all clinical or all surrogate
primary endpoint results were arbitrated based on the relative importance of the
significant endpoints in question. For trials that did not specifically designate a
primary outcome, any outcomes reported in the trial’s abstract were considered
primary and the overall study was categorized using the scheme described
previously. Trials that presented analyses in a solely descriptive manner or that
lacked a designated comparison against which to judge the statistical significance of
reported results were noted as “non-inferential” and excluded from analyses of
association. Trials categorized as “positive” were judged to report overall favorable
results, whereas those categorized as “negative” or “not significant” were judged to
report overall unfavorable results.
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Statistical Analysis
We used descriptive statistics to characterize the proportion of trials
registered, the proportion registered retrospectively, as well as the proportion
registered after initial primary outcome ascertainment, overall, and stratified by
specialty journal and trial characteristics. We additionally determined the
proportion of trials with concordant registered and published primary outcome
measures and the proportion reporting favorable results, overall, and stratified by
journal, registration timeliness, intervention, funding source, location, allocation,
and enrollment. We used Chi-squared testing to assess differences in registration
and registration timeliness by journal and by each of the aforementioned trial
characteristics. We also used Chi-squared testing to assess differences in primary
endpoint concordance and study results by journal, trial characteristics, and
timeliness of registration. In cases involving small sample sizes, we used Fisher’s
exact tests in place of Chi-squared testing. All tests were performed using a 2-sided
type I error level of 0.006 to account for multiple comparisons. Statistical analyses
were performed using JMP Pro Version 11.2.0 (SAS Institute, Inc.).

RESULTS
Search Results
We reviewed 6,869 original research reports published in the period
between January 1, 2010 and December 31, 2015 to identify the 50 most recent
primary trial publications in each of ten high-impact specialty journals (Figure 1).
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Figure 1. Construction of study sample comprising the 50 most recent clinical trial publications
appearing in each of ten high-impact specialty journals between January 1, 2010 and December 31,
2015.

Notes: a Includes post hoc analyses, exploratory analyses, analyses of secondary outcomes, long-term
follow-up, interim analyses, pooled analyses, extension trials, and studies utilizing data derived from
clinical trials
b Includes case reports, case series, modeling studies, twin studies
Abbreviations: AJP = American Journal of Psychiatry; AJRCCM = American Journal of Respiratory and
Critical Care Medicine; AON = Annals of Neurology; Gast. = Gastroenterology; Hep.= Hepatology; JACI =
Journal of Allergy and Clinical Immunology; JCO = Journal of Clinical Oncology; JACC = Journal of the
American College of Cardiology; JASN = Journal of the American Society of Nephrology

Two journals (Annals of Neurology, n=37; Journal of the American Society of
Nephrology, n=35) published fewer than 50 eligible primary trial publications in this
period. After excluding publications describing phase I trials (n=44) and trials
initiating enrollment prior to July 2005 (n=60), there were 472 publications
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reporting the primary results of 486 clinical trials (14 articles described multiple
trials).
Characteristics of Eligible Trials
Among our final sample of 486 trials, 76% (n=372) were randomized studies
(Table 1). Eighty-one percent (n=392) assessed interventions involving drugs,
devices, or vaccines/biologicals. Forty-four percent received industry funding
(n=216), and just over half recruited patients at one or more sites located in the US
(n=250; 51%). Phase II designations were most frequent (n=190; 39%). Median
enrollment across all trials was 127 participants (interquartile range [IQR], 49-300).
Eighty-nine percent (n=433) of trials were published since 2013. The median
impact factor among journals in our sample was 12.24 (range, 8.5-21.0).
Table 1. Characteristics of clinical trials published in ten high-impact specialty journals between
January 1, 2010 and December 31, 2015 (N=486).

Interventiona
Drug
Device
Vaccine or biological
Other
Phaseb
Phase II
Phase III
Phase IV
Not listed
Randomization
Yes
No
Fundingc, d
Industry
Non-industry
Enrollment
≥ 100
< 100
Location(s)
US only
US and international

n

(%)

287
46
86
102

59.1
9.5
17.7
21.0

190
110
46
153

39.1
22.6
9.5
31.5

372
114

76.5
23.5

216
270

44.4
55.6

280
206

57.6
42.4

166
84

34.2
17.3
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International only
Trial registrye
ClinicalTrials.gov
EU-CTR
ISRCTN
Other registriesf

236

48.6

383
76
24
47

87.2
17.3
5.5
10.7

Notes: a Clinical trials may have involved more than one intervention type
b Thirteen trials were designated as Phase II/Phase III
c Funding information was not reported in the publications of 5 trials, all of which were unregistered;
these trials were designated as not reporting industry funding.
d Industry funding includes partial or full support.
e 439 trials were registered. Percentages are expressed based on a denominator of 439. 81 trials were
registered in multiple registries, hence percentages may not sum to 100.
f “Other registries” includes: Australia New Zealand Clinical Trials Register (ANZCTR), Chinese
Clinical Trial Registry (ChiCTR), Clinical Trial Registry of India (CTRI), German Clinical Trials Register
(DRKS), Japan Pharmaceutical Information Center Clinical Trials Information (JAPIC-CTI),
Netherlands Trial Register (NTR), University Hospital Medical Information Network (UMIN) (a
Japanese registry).
Abbreviations: EU-CTR = European Union Clinical Trials Register; ISRCTN = International Standard
Randomised Controlled Trial Network

Registration
Forty-seven (10%) of the 486 trials were not registered. Two trials (0.4%)
reported registration numbers for which a matching registration could not be
located. Of 439 registered trials, 33 (8%) did not report a trial registration number
in their publication, requiring further searching to identify corresponding
registrations records. All registered trials (n=439, 100%) were registered in
registries endorsed by ICMJE, though duplicate registrations across more than one
registry were not uncommon (n=81; 18%). Eight-seven percent of registered trials
(n=383) were registered on ClinicalTrials.gov, which accounted for 79% of initial
trial registrations (n=346).
Specialty journals differed in their rates of trial registration (Table 2)
(p<0.001). Annals of Neurology published the greatest proportion of unregistered
trials (43%; 16 of 37), accounting for 34% of trials without registration; in
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comparison, all trials published in the Journal of Clinical Oncology and Blood, both of
which primarily publish oncology trials, were registered. Registration was more
frequent among trials involving drugs, devices, or vaccines/biologicals (361 of 392;
92%) compared to those involving other intervention types (78 of 94; 83%), though
this did not reach statistical significance (p=0.007). Randomization, larger trial size,
enrollment sites in the US, and industry funding were each additionally associated
with higher rates of registration (Table 3).
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Table 2. Registration, timeliness of registration, and primary endpoint concordance among clinical trials published in ten high-impact US medical
specialty society journals, stratified by journal.
Total
(column
%)

Registration

Total

486 (100)

47 (9.7)

99 (22.6)

Retrospective after
initial primary
endpoint
ascertainment (%)c, d
67 (15.3)

AJP

52 (10.7)

6 (11.5)

15 (32.6)

14 (30.4)

AJRCCM

51 (10.5)

4 (7.8)

Unregistere
d (%)b

Timeliness of Registrationa
P
Value

Retrospectiv
e (%)c

P
Value

7 (14.9)
<0.00
1

7 (14.9)
0.21

249 (56.7)
17 (37.0)

282
(66.4)
45 (86.5)

28 (59.6)

29 (60.4)

8 (38.1)

24 (72.7)

.049

37 (7.6)

16 (43.2)

Blood

52 (10.7)

0 (0.0)

9 (17.3)

4 (7.7)

26 (50.0)

23 (60.5)

Gast.

53 (10.9)

1 (1.9)

7 (13.4)

7 (13.5)

30 (57.7)

30 (68.2)

Hep.

50 (10.3)

7 (14.0)

9 (20.9)

4 (9.3)

27 (62.8)

21 (60.0)

JACI

51 (10.5)

7 (13.7)

12 (27.3)

5 (11.4)

25 (56.8)

27 (64.3)

JCO

51 (10.5)

0 (0.0)

10 (19.6)

4 (7.8)

35 (68.6)

28 (57.1)

JACC

50 (10.3)

4 (8.0)

16 (34.8)

15 (32.6)

34 (73.9)

30 (66.7)

JASN

39 (8.0)

2 (5.1)

9 (24.3)

4 (10.8)

19 (51.4)

25 (64.1)

Notes:

3 (14.3)

0.004

Primary
Endpoint Results
Favorable P
(%)f
Value

AON

a Among

5 (23.8)

P
Value

Primary Endpoint
Concordancee
Concordan P
t (%)c
Value

439 registered trials, we could not determine timeliness of registration for 2 (1 published in Gastroenterology and the other in JCO), as
enrollment start date was missing from registrations. We excluded these 2 trials from analyses of association pertaining to overall timeliness of
registration and timeliness of registration relative to initial primary outcome ascertainment.
b Percentages are expressed as fraction of total trials in each row.

0.11
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c Percentages

are expressed as fraction of registered trials in each row.
Due to the nature of the primary outcome (i.e. median survival), we could not determine if retrospective registration occurred after initial primary
outcome ascertainment in 8 cases: 1 in Blood; 1 in Hepatology; 2 in JACI; and 4 in JCO. These trials were excluded from analyses of association pertaining
to timeliness of registration relative to initial primary outcome ascertainment.
e Twenty-six of 439 registered trials did not have a primary outcome designated in their publication and were therefore excluded from analyses of
association pertaining to primary endpoint concordance.
f Percentages are expressed as fraction of trials in each journal for which primary endpoint favorability could be judged (row totals not shown).
Abbreviations: AJP = American Journal of Psychiatry; AJRCCM = American Journal of Respiratory and Critical Care Medicine; AON = Annals of Neurology;
Gast. = Gastroenterology; Hep.= Hepatology; JACI = Journal of Allergy and Clinical Immunology; JCO = Journal of Clinical Oncology; JACC = Journal of the
American College of Cardiology; JASN = Journal of the American Society of Nephrology
d
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Table 3. Registration, timeliness of registration, primary endpoint concordance, and study results across clinical trials published in ten high-impact US
medical specialty society journals, stratified by trial characteristics.
Registration
Total
(column
%)

Unregistered
(%)b

Total

486 (100)

47 (9.7)

Drug/Device
/ Biological
Yes

392 (80.7)

31 (7.9)

94 (19.3)

16 (17.0)

216 (44.4)

11 (5.1)

270 (55.6)

36 (13.3)

250 (51.4)

15 (6.0)

236 (48.6)

32 (13.5)

372 (76.5)

23 (6.2)

114 (23.5)

24 (21.1)

280 (57.6)

9 (3.2)

No
Fundinga
Industry
Non-industry
Location
≥ 1 US site
Non-US
Randomized
Yes
No
Enrollment
≥ 100

Timeliness of Registrationc, d
P
Value

Retrospective
(%)e

P
Value

99 (22.6)

Primary Endpoint
Concordanceg, h

Retrospective
after initial
primary endpoint
ascertainment
(%) e, f
67 (15.3)

P
Value

42 (11.6)

<
0.001

Concordant
(%)e

P
Value

249 (56.7)

Primary
Endpoint
Resultsi
Favorable
(%)j

282
(66.4)
0.009

0.007
3

65 (18.0)

<
0.001

34 (43.6)
0.002
3

25 (12.2)

25 (32.1)
<
0.001

74 (31.6)
0.004
8

35 (14.9)

<
0.001

79 (22.6)

58 (21.4)

<
0.001

0.91

56 (16.0)

<
0.001

43 (15.9)

0.014

117
(65.7)
165
(66.8)

0.82

133 (56.6)

0.44

148
(65.8)
134
(67.0)

0.79

0.10

231
(64.0)
51 (79.7)

0.01

0.47

161
(62.7)

0.046

116 (56.9)
0.39

11 (12.2)
0.49

131 (63.9)

195 (55.9)
54 (60)

0.69

162 (59.8)

0.16
218
(64.7)
64 (72.7)

118 (50.4)

44 (21.6)

20 (22.2)
<
0.001

23 (9.8)

216 (59.8)
33 (42.3)

49 (20.9)

64 (31.4)
<
0.001

18 (8.8)

P
Value

21

< 100

206 (42.4)

38 (18.5)

41 (24.4)

24 (14.3)

87 (51.8)

121
(72.0)

Notes:
a Trials receiving either full or partial industry support were designated as having received industry funding.
b Percentages are expressed as the fraction of total trials in each row.
c Trials registered > 30 days after enrollment start were considered to have been registered retrospectively. Note that ICMJE policy mandates
registration prior to enrollment start.
d Among 439 registered trials, we could not determine timeliness of registration for 2 (1 published in Gastroenterology and the other in Journal of
Clinical Oncology), as enrollment start date was missing from registrations. We excluded these 2 trials from analyses of association pertaining to overall
timeliness of registration and timelines of registration relative to initial primary outcome ascertainment.
e Percentages are expressed as the fraction of registered trials (total - unregistered) in each row.
f Due to the nature of the primary outcome (i.e. median survival), we could not determine if retrospective registration occurred after initial primary
outcome ascertainment in 8 cases: 1 in Blood; 1 in Hepatology; 2 in Journal of Allergy and Clinical Immunology; and 4 in Journal of Clinical Oncology.
These trials were excluded from analyses of association pertaining to timeliness of registration relative to initial primary outcome ascertainment.
g Registered and published primary endpoints were considered concordant if they did not differ in any of the following 3 domains: number of outcomes,
outcome definition(s), or outcome time frame(s).
h Twenty-six of 439 registered trials did not have a primary outcome designated in their publication and were therefore excluded from analyses of
association pertaining to primary endpoint concordance.
i Primary endpoint favorability could not be judged for 61 trials. These trials were excluded from analyses of association pertaining to primary endpoint
favorability.
j Percentages are expressed as the fraction of trials in each row for which primary endpoint favorability could be judged (row totals not shown)
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Timeliness of Registration
Among the 439 registered trials, 99 (23%) were registered retrospectively
(i.e. at least 30 days after beginning patient enrollment) based on the enrollment
start date reported in the registry. The median delay in registration was 8 months
(IQR, 5-19; range, 1-88). Sixty-seven (68%) of the 99 retrospectively registered
trials, or 15% of all 439 registered trials, were registered late enough to have
potentially permitted premature examination of trial results after collection of the
primary outcome among participants enrolled at inception (Table 4). Of 302 trials
with a registered primary completion date, 7 (2%) were registered after reported
completion of data collection for the trial’s primary outcomes. Two (2%) of 88
retrospectively registered trials that listed a manuscript submission date were
found to have registered after submission of the manuscript to the publishing
journal. Only one (1%) of 99 retrospectively registered trials acknowledged late
registration in its publication, attributing the delay to principal investigator
oversight and offering access to the original study protocol upon request.[34]
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Table 4. Illustrative examples of prospective trial registration, retrospective trial registration occurring without possibility for informed interim
analyses, and retrospective registration occurring with possibility for interim analyses.
Reference
J Am Soc Nephrol. 2010
Jun;21(6):1052-61.
J Allergy Clin Immunol. 2015
Mar;135(3):670-5.e3.
J Allergy Clin Immunol. 2015
Apr;135(4):922-29.e6.

Registration
No.
NCT00426153

Registration
Date
1/22/2007

Enrollment
Start
1/31/2007

Registration
Delay
N/A

NTR2205

2/8/2010

1/1/2010

1 month

NCT02024659

12/27/2013

9/30/2010

39 months

Registered Primary
Endpoint (Time Frame)
Percentage change in liver
volume (12 months)
Induced sputum neutrophil
and eosinophil percentage
counts (9 weeks)

Registration Timing

Nasal polyp size (2 weeks)

Retrospective (after
initial primary
endpoint
ascertainment)

Prospective
Retrospective
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Journals did not differ significantly in their rates of overall timely
registration (p=0.21), but did differ in their rates of registration before initial
primary outcome ascertainment (p=0.004) (Table 2). Trials involving industry
funding, enrollment sites in the US, and assessing drugs, devices, or
vaccines/biological each had higher rates of prospective registration as compared to
those without industry funding, enrolling at only non-US sites, and assessing nonregulated interventions (Table 3).
Primary Endpoint Concordance
Among the 439 registered trials, 15 (3.4%) failed to register a primary
outcome at initial registration, though 14 of these 15 published a primary endpoint.
Twenty-six trials, nearly all of which (n=25; 96%) registered a primary endpoint at
initial registration, did not explicitly name a primary endpoint in their publications.
Of 413 registered trials designating at least one primary outcome in their
publications, sixty percent (n=249) published primary endpoints fully concordant
with those specified at initial registration. Twenty-six percent (n=109) published
primary endpoints discrepant from those initially registered. Seventy-eight (72%)
of these 109 discrepancies were based on either the number or definition of
primary endpoints, whereas 31 (28%) were based on the specified time frame of
primary outcome ascertainment. The remaining 13% (55 of 413) registered initial
primary endpoints that were too poorly specified to permit comparison with
published endpoints. Among the 346 trials registered first on ClinicalTrials.gov, 19
(5%) trials listed original primary outcome measures that were submitted at least
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30 days subsequent to the reported registration date. Seven (37%) of these 19
involved trials whose registration was already retrospective.
Among the 249 trials reporting discrepant published and registered primary
endpoints, 80% (n=198) were registered prospectively; 20% (51 of 249) were
retrospectively registered. Neither overall timely registration (p=0.31) nor
registration prior to initial primary outcome ascertainment (p=0.29) was associated
with concordance between registered and published primary endpoints. Even so,
just 1 of 7 trials determined to have been registered after their primary completion
date published outcomes concordant with those initially registered, despite the
significant delay in registration.
Favorability of Trial Results
Among the 486 trials in our sample, 425 (87%) reported primary endpoint
results from which inferences about the statistical significance of reported outcomes
could be drawn; 61 trials (13%) were non-inferential, including descriptive or
single-arm studies without a specified comparator, and could not be judged
accordingly. Sixty-six percent (n=282) of the 425 inferential trials reported
favorable primary outcome results. Of 143 (34%) trials reporting unfavorable
primary outcome results, most (n=135; 94%) reported findings that were not
significant, while 8 (6%) reported negative results. Unregistered trials were more
likely to report favorable results (31 of 35; 89%) than were registered trials (251 of
390; 64%) (p=0.004), irrespective of registration timing. Favorable results
reporting appeared to be more frequent among trials potentially vulnerable to
unaccounted primary endpoint modifications (73 of 96; 76%), which included those
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that were unregistered and those registered after initial primary outcome
ascertainment, compared to those registered prior to initial primary outcome
ascertainment (206 of 321; 64%), but our findings did not reach statistical
significance (p=0.03).

DISCUSSION
Our study of clinical trials recently published in ten high-impact specialty
society journals, all requiring trial registration, found that 10% of published trials
were unregistered. Moreover, among registered trials, nearly one quarter were
registered retrospectively. Of these, more than two-thirds, or 15% of all registered
trials, were registered late enough after participant enrollment to afford
opportunity for unaccounted protocol modifications based on potential premature
analyses of observed primary endpoint data. Irrespective of registration timing,
post-registration modifications to primary endpoints were frequent, as 26% of trials
published primary outcomes that differed from those specified at initial registration.
Finally, unregistered trials reported favorable results at a higher rate than trials that
had registered. The publication of unregistered trials and trials registered after
initial primary outcome ascertainment raises concerns about selective reporting
and the integrity of reported endpoints, as these trials are vulnerable to potential
changes obscured from public record.
Despite policies to improve registration rates,[32, 35, 36] publication of
unregistered trials persists. Our study demonstrates that even the highest impact
journals associated with US professional medical societies publish unregistered
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trials, albeit some more frequently than others. Consistent with earlier studies,[1319] our findings suggest that, more than a decade since implementation of policies
designed to promote universal registration, continued efforts are needed to ensure
that all trials are registered, even among those that are published. Registration was
more frequent among trials assessing FDA-regulated interventions as compared to
trials evaluating non-regulated interventions, such as behavioral and procedural
interventions, as prior research has suggested.[16] We additionally noted higher
registration rates among larger trials and those receiving industry support. As each
of the specialty society journals we assessed requires trial registration, our results
indicate that some journals do not consistently adhere to their own registration
policies. Prior work indicates that journals may in fact relax their own registration
requirements for various reasons, including reluctance to penalize otherwise sound
research, apprehension about losing manuscripts to rival journals, and
misconceptions about the applicability of registration policies.[26] Regardless of the
rationale, publication of unregistered trials risks dissemination of trials lacking
accountability and potentially influenced by selective reporting. Our study and prior
work examining cardiovascular clinical trials demonstrate that unregistered trials
more frequently report favorable findings,[37] though a recent study examining a
large sample of unselected trials found only a marginal association.[38]
Nevertheless, stricter adherence to registration policies may help prevent the
publication of trials that are selectively reporting results, biasing the medical
literature.
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While registering trials can help mitigate selective reporting, registration
must occur prospectively, in accordance with ICMJE policy, to effectually detect and
deter biased reporting. Despite the importance of timely registration, nearly one in
four trials in our sample was published despite having been registered
retrospectively. Furthermore, the majority of late registrations were delayed to such
a degree after enrollment of the trials’ first participants that it could have permitted
investigators the opportunity to amend primary endpoints after conducting interim
analyses. For trials registered after ascertainment of endpoints, it is nearly
impossible to ascertain the degree to which published reports diverge from original
protocol given the potential for modifications occurring covertly pre-registration.
While the frequency of post-registration endpoint modifications does not appear to
depend on the timeliness of trial registration, we cannot comment on the frequency
and effects of pre-registration protocol modifications beyond identifying situations
in which they could have potentially occurred.
This study’s findings are consistent with prior research that timely
registration is more frequent among certain trial types, including those involving
FDA-regulated interventions and those receiving industry support.[14, 21]
Compared with existing studies,[14, 21, 23] however, retrospective registration was
overall less frequent in our sample. Notwithstanding the possibility that specialty
society journals are in better overall adherence, there are several methodological
explanations for this observation, including utilization of each trial’s earliest
registration record, which is not always reported in publications, application of a
30-day grace period between enrollment initiation and registration, and our
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conservative treatment of month-based reporting of enrollment start dates to
ensure that true prospective registrations were not misclassified. Only one prior
study has assessed timeliness of registration as it relates to its potential effect on
reported outcomes, specifically within the context of the six highest impact general
medical journals.[21] While late registration was less frequent among specialty
society journals as compared to the general medical journals assessed in the prior
study (23% v. 28%), this study observed a higher proportion of late registrations
that potentially permitted an opportunity for endpoint modification informed by
potential interim analyses (15% vs. 8%).
Implications of Findings
Because journals control the dissemination of research, they are well
positioned to help ensure the integrity of published material, which includes
adequate and timely registration of published trials.[39] Specialty society journals,
in particular, bear a significant responsibility to this end, as they publish trials that
are of great interest and potential influence to their targeted clinical readerships. As
part of the peer-review process, journals generally require the disclosure of trial
registration information, though discrepancies between registered and reported
material do not appear to influence the decision to accept or reject manuscripts,[40]
suggesting that editors may not scrutinize or may choose to disregard discrepancies.
If oversight is in fact the driver, greater attention paid to trial registration during
editorial review may reduce the rate at which potentially biased trials are published,
including those that are unregistered or retrospectively registered.
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However, while ICMJE policy advocates barring retrospectively registered
trials from publication, it acknowledges that editors may judge for themselves the
circumstances surrounding late registration and its potential bearing on reported
endpoints.[32] Accordingly, our findings may instead stem from editors deliberately
choosing to publish non-compliant trials, which they may do for reasons suggested
previously.[26] A survey of editors from journals endorsing ICMJE guidelines found
that two-thirds would consider publication of retrospectively registered trials,
though just 13% indicated that consideration would be situation-dependent.[25]
For journal editors weighing the decision to publish such trials, ascertaining
whether registration was sufficiently delayed to have potentially biased the
reported results may help guide decisions regarding appropriate exceptions. The
significance of study findings should be carefully evaluated in the decision to accept
or reject given the potential for bias that exists among unregistered or
retrospectively registered trials. If journals elect to move forward with publishing
these trials, steps should be taken to ensure that original trial protocols, approved
by and obtained directly from institutional review boards, are made publicly
available. Additionally, as ICMJE policy suggests, publication of non-compliant trials
should be accompanied by published statements explaining why registration did not
occur or was delayed and, further, why journal editors nonetheless judged the trial
fit for publication.[32] Just one retrospectively registered trial in our sample
addressed its delayed registration, offering to make available its original protocol
upon request. While routine posting of original protocols for all trials, regardless of
registration compliance, may mitigate concerns regarding biased reporting, such
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practices are infrequent.[41] Among journals in our sample, only the Journal of
Clinical Oncology requires submission and publication of trial protocols, albeit only
for phase II and III trials.[42]
Limitations
This study has several limitations. First, the ICMJE definition of a clinical trial
is subject to interpretation, particularly in terms of what constitutes a “healthrelated intervention” and a “health outcome”. ICMJE adopted an expanded clinical
trial definition in 2007 clarifying the scope of these terms.[43] Nevertheless,
confusion regarding the applicability of registration requirements for interventional
clinical studies may exist among investigators and journals editors. While ICMJE
believes that investigators should err towards prospectively registering all
interventional studies of human subjects in cases of uncertainty,[43] subjectivity in
classifying studies as “clinical trials” may have influenced our observed frequency of
unregistered trials, particularly in cases where the applicability of the ICMJE
definition may not be patent. Second, this analysis does not represent a perfect audit
of ICMJE registration policy, given its concession of a 30-day grace period and
exclusion of Phase I studies. Nevertheless, this study aimed to capture the spirit of
the policy rather than the strict letter of the law to account for potential flexibility
on the part of journals in the case of minimally delayed registrations. Third, our
sample by design comprised a group of clinical trials recently published in select
high-impact specialty society journals; accordingly, our findings may not be
representative of overall trial registration patterns or of all specialty society
journals. Nevertheless, this study selected the highest-impact specialty journals, the
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most prestigious in their respective fields, which are expected to adhere to the
highest standards of trial registration practices. Fourth, our cross-sectional analysis
did not examine potential improvements in trial registration within journals over
time nor account for the fact that journals may have adopted the ICMJE’s
registration policy at different time points since its implementation. Even so, the
earliest trials in our sample were published in January 2010, nearly half a decade
since the policy went into effect, with 89% of sampled trials being published in a
three-year span since 2013. Finally, our study only assessed frequency of
modifications to primary endpoints, though selective reporting may manifest
through post-registration protocol modifications to other elements of trial design,
including secondary endpoints and sample size, which were not examined.
Moreover, this study is only able to comment on the possibility of retrospective
registration to invite unaccounted interim analyses or pre-registration protocol
modifications and not on whether such analyses or modifications actually occurred.
Such information could only be ascertained through examination of original trial
protocols, which are often unavailable and lack complete information.[41]
Additionally, how informative interim analyses are, in some cases, depends on the
trial’s experience of participant accrual, details of which are also generally not
readily accessible.
Conclusions
Our large study of clinical trials published in ten high impact specialty society
journals demonstrates that registration of trials continues to fall short of the ICMJE’s
standards necessary to ensure a complete and unbiased evidence base. Ten percent
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of published trials were unregistered. Moreover, nearly a quarter of registered trials
were registered late, the majority of these late enough to afford investigators the
chance to implement modifications potentially informed by collected data.
Unregistered trials reported favorable study findings at a higher rate than
registered trials, raising concerns that lack of accountability may exert undue
influence on reported results. While journals should generally avoid publishing
improperly registered trials, exceptions should be acknowledged, justified, and
furthermore accompanied by an evaluation and public posting of the study’s original
protocol. Greater adherence to the ICMJE’s prospective trial registration policy may
help reduce the publication of studies failing to meet proper standards and improve
the integrity of published trial results.
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